Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells.

Nature communications·2026
Same author

Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors.

Science translational medicine·2025
Same author

Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma.

Journal for immunotherapy of cancer·2025
Same author

Dendritic cell progenitors engineered to express extracellular-vesicle-internalizing receptors enhance cancer immunotherapy in mouse models.

Nature communications·2025
Same author

Erratum: Trajectories of macrophage ontogeny and reprogramming in cancer.

iScience·2025
Same author

Trajectories of macrophage ontogeny and reprogramming in cancer.

iScience·2025

Related Experiment Video

Updated: Feb 17, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

14.7K

Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy.

Martina Schmittnaegel1, Michele De Palma1

  • 1The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.

Trends in Cancer
|December 5, 2017
PubMed
Summary

Angiogenic blood vessels create an immunosuppressive tumor environment by hindering T cell entry. Reprogramming these vessels, such as via angiopoietin-2 blockade, can enhance T cell trafficking and improve cancer immunotherapy effectiveness.

More Related Videos

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

12.0K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.5K

Related Experiment Videos

Last Updated: Feb 17, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

14.7K
A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

12.0K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.5K

Area of Science:

  • Oncology
  • Immunology
  • Vascular Biology

Background:

  • Angiogenic blood vessels in tumors foster an immunosuppressive microenvironment.
  • This environment limits T cell infiltration, a critical factor for effective anti-tumor immunity.
  • Current cancer immunotherapies can be hindered by these vascular characteristics.

Purpose of the Study:

  • To investigate the role of angiogenic blood vessels in shaping the tumor immune microenvironment.
  • To explore the potential of targeting angiogenic blood vessels to enhance T cell trafficking.
  • To assess the impact of vascular reprogramming on the efficacy of cancer immunotherapies.

Main Methods:

  • Analysis of tumor blood vessel characteristics and their impact on immune cell infiltration.
  • Intervention studies involving angiopoietin-2 blockade in preclinical tumor models.
  • Evaluation of T cell trafficking and immune checkpoint blockade (ICB) efficacy following vascular modulation.

Main Results:

  • Angiogenic blood vessels were confirmed to impede T cell extravasation into tumors.
  • Functional reprogramming of these vessels, specifically through angiopoietin-2 blockade, improved T cell infiltration.
  • Enhanced T cell trafficking correlated with improved responses to ICB and other immunotherapies.

Conclusions:

  • Targeting angiogenic blood vessels represents a viable strategy to overcome immune suppression in the tumor microenvironment.
  • Vascular reprogramming can synergize with existing immunotherapies to enhance anti-tumor responses.
  • Modulating angiopoietin-2 offers a promising therapeutic avenue for improving cancer immunotherapy outcomes.